Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Altered synaptic function in Alzheimer's disease.

Karen F S Bell1, A Claudio Cuello

  • 1Department of Pharmacology and Therapeutics, McGill University, 3655 Sir William Osler Promenade, Montreal, QC, Canada H3G 1Y6.

European Journal of Pharmacology
|August 5, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of plasma biomarkers with age in the presenilin-1 E280A autosomal dominant Alzheimer's disease kindred.

The journal of prevention of Alzheimer's disease·2026
Same author

Web-based LAS-FNAME and blood biomarkers in autosomal dominant Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Human in vitro and rodent in vivo models highlight progressive mitochondrial dysfunction as a starting point of cerebral amyloidosis.

Neurobiology of aging·2026
Same author

Association between basal forebrain volume and age in the presenilin-1 E280A autosomal dominant Alzheimer's disease kindred.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Clinical Manifestations.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Clinical Manifestations.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

Astaxanthin inhibits platelet-mediated thrombosis via suppression of bidirectional αIIbβ3 signaling.

European journal of pharmacology·2026
Same journal

Repurposing of alogliptin to mitigate experimentally-induced ulcerative colitis and its associated pulmonary injury in rats through regulating inflammatory, necroptotic, and ER stress pathways.

European journal of pharmacology·2026
Same journal

Erianin ameliorates liver fibrosis through the PRDX3/NLRX1 axis.

European journal of pharmacology·2026
Same journal

4-Octyl itaconate attenuates renal calculi formation by inhibiting ferroptosis and oxidative stress via the Nrf2-HO-1/SLC7A11 axis.

European journal of pharmacology·2026
Same journal

VER155008 rescues cognitive impairment in P301S tauopathy mice by promoting HSPA8-mediated lipophagy.

European journal of pharmacology·2026
Same journal

Okanin alleviates osteoarthritis by suppressing oxidative stress and pyroptosis via Nrf2/HO-1 activation.

European journal of pharmacology·2026
See all related articles

Alzheimer's disease impacts brain synapses. Research shows amyloid pathology affects neurotransmitter terminals differently, with cholinergic and glutamatergic neurons being most vulnerable.

Area of Science:

  • Neuroscience
  • Neuropathology
  • Molecular Biology

Background:

  • Alzheimer's disease (AD) is the primary cause of dementia in older adults, characterized by memory and learning decline.
  • Synaptic density is a key indicator of cognitive impairment in AD, making synaptic disconnection mechanisms crucial to understand.
  • Investigating neurotransmitter-specific changes in presynaptic boutons offers insight into AD pathology progression.

Purpose of the Study:

  • To examine the neurotransmitter-specific status of cortical presynaptic bouton populations in mouse models of Alzheimer's-like amyloid pathology.
  • To assess the involvement of different neurotransmitter systems throughout the progression of AD pathology.
  • To identify potential explanations for observed neurotransmitter-specific vulnerabilities.

Main Methods:

Related Experiment Videos

  • Utilized transgenic mouse models exhibiting Alzheimer's-like amyloid pathology.
  • Analyzed distinct cortical presynaptic bouton populations.
  • Assessed neurotransmitter-specific changes in relation to disease progression.

Main Results:

  • Amyloid pathology progression demonstrates a neurotransmitter-specific pattern.
  • Cholinergic terminals exhibit the highest vulnerability.
  • Glutamatergic terminals are affected subsequently, followed by more resilient GABAergic terminals.

Conclusions:

  • The findings support a neurotransmitter-specific progression of Alzheimer's disease pathology.
  • Vulnerabilities may be linked to factors such as metabolic demand, trophic support, and receptor-mediated activation.
  • Understanding these specific vulnerabilities is vital for developing targeted therapeutic strategies.